In the digital age, focusing all of your attention on digital advertising might seem practical—especially when your patient recruitment advertising budget is minimal. While digital ads are relatively inexpensive and have the ability to reach a large audience, digital ads alone might not be the most effective way to recruit patients. In this article, we’ll discuss the value of traditional media and offer some simple, cost-effective ways to utilize traditional marketing collateral to maximize ROI across your entire campaign.
In today’s patient recruitment setting, advertising budgets seem to be continuously shrinking, but the desired results of advertising campaigns are still the same – recruit patients and finish the study on time, within the given budget. Having access to your site’s advertising metrics allows you to maximize your marketing return on investment (ROI), and can strengthen your request for sponsor funds. How do you get those metrics without breaking the bank? This article will provide tips for requesting sponsor ad funds and maximizing your advertising ROI by creating a detailed ad plan, complete with real metrics gathered from study-specific landing pages.
Contract negotiations are just that—negotiations. Some back and forth is to be expected when building an equitable set of contract terms, but at what point do terms become non-negotiable? Here are five examples of some the major deal-breakers in contract negotiations:
With over 1.15 billion active users, Facebook is becoming an increasingly important way for clinical research sites to recruit patients for their studies. While patient populations certainly exist on Facebook, connecting with them on the world’s largest social network isn’t always easy. In order for patients to find your study in an online space already saturated with ads, creating advertisements with strong visual imagery and good calls to action is vital.
Clinical research coordinators are an incredibly important part of the clinical research process. Their role has continued to evolve in recent years, as clinical trials have continued to grow in complexity.
For many research sites, navigating the clinical trial landscape can be very intimidating. Site networks offer many benefits to research sites, but here are five main reasons why every clinical research site should consider joining a site network:
Stem Cells Edited to Fight Arthritis – Read More >
Researchers at the Washington University School of Medicine and Shriners Hospitals for Children have rewired stem cells from mice in an effort to reduce inflammation caused by arthritis and other conditions. These stem cells are developed into cartilage cells that produce a biologic anti-inflammatory drug that may be able to replace arthritic cartilage, protecting joints and other tissues from further damage.
Site selection is a complex process composed of multiple factors on which research sites are evaluated. It may seem as if your success is solely in the hands of sponsors and CROs, but there are several things you can do to help your site get selected on more studies. Here are three tips from the site selection and business development team at PharmaSeek:
Advertising plays an important role when it comes to recruiting patients for clinical trials, but it’s often underutilized by sites or not used at all. Whether this is due to a lack of internal staffing or expertise, there is a lot of potential going untapped when sites bypass study advertising.
One of the negative aspects of clinical trials is the possibility that a patient will suffer an injury or illness as a result of their study participation. As such, one of the most important pieces of a contract is the subject injury language. ‘Subject Injury’ is defined as an injury, illness, adverse event/reaction, or death caused by a study subject’s involvement in a clinical research study. Prior to the study, the research site and the study sponsor should come to an agreement on what exactly constitutes a Subject Injury, and who pays in the event of a Subject Injury.
As many marketers know, the sustainability of print advertisements has been thoroughly questioned in today’s digital age. In June of 2012, Forbes Magazine published an article about this very issue—taking a stance that surprised many at the time. Forbes stated, “While many businesses have completely migrated their advertising efforts to the web because of its cost effectiveness, exposure potential and convenience, print still maintains its stance as a powerful and necessary component of an ad campaign.”
A Clinical Trial Management System (CTMS) is a computer software system that manages data within a clinical trial. The system centralizes the administrative components of each study, including billing, reporting and tracking. Many research sites, institutions, sponsors, and CROs use these systems to monitor clinical trials. Below are 3 key benefits of implementing a CTMS.
Finding research sites that are capable and willing to conduct your clinical trials can be a burdensome task. Since 1995, Pharmaseek has partnered with both sponsors and CROs to identify clinical research sites for clinical trials in virtually every therapeutic area. What started as a group of twelve research sites has grown into a network of approximately 250 investigative research sites, the largest network of its kind. Research facilities in the PharmaSeek network range from small practices to large academic institutions.
A crucial component to having a successful clinical trial is enrolling participants, but not just any participants—the right ones. With already full plates, where do busy sites begin the process of patient recruitment advertising?
Much has been written about the changing clinical research landscape, and more importantly, the implications these changes are having on small, independent research sites. The first major change was the implementation of preferred site programs by many larger contract research organizations (CROs). The second, and more recent development, is the actual acquisition of research sites and site networks by CROs. Separate of both of these trends, is the premise that “big data” will give larger health systems a competitive advantage, allowing them to reestablish their dominance in Phase II and III research. Each of these themes are explored in greater detail below.